Neuberger Berman Group
FOMX

Neuberger Berman Group’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Neuberger Berman Group’s Portfolio FOMX Stock Details FOMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-45,000
Closed -$500K – 1669
2016
Q4 		$500K Sell
45,000
-20,000
-31% -$188K ﹤0.01% 1290
2016
Q3 		$602K Buy
+65,000
New +$543K ﹤0.01% 1223
2015
Q4 		– Sell
-62,500
Closed -$458K – 1597
2015
Q3 		$458K Sell
62,500
-28,200
-31% -$287K ﹤0.01% 1297
2015
Q2 		$930K Buy
+90,700
New +$1M ﹤0.01% 1224

Other funds holding FOMX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Neuberger Berman Group's FOMX Position: Q1 2017 in Review

Neuberger Berman Group sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q1 2017, closing a stake of 45,000 shares — an estimated $500K sold.

Neuberger Berman Group first reported a position in FOMX in Q2 2015 and held it in 4 quarters. The position peaked at $930K in Q2 2015. 67 funds tracked by Wall St. Rank hold FOMX as of Q1 2017.

  • Neuberger Berman Group reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q1 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 45,000 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q1 2017, an estimated $500K.
  • Neuberger Berman Group first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q2 2015 and held it in 4 quarters.
  • Neuberger Berman Group's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $930K in Q2 2015.
  • 67 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q1 2017.

Based on Neuberger Berman Group's 13F filing for Q1 2017, filed 10 May 2017.